Job Trends
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Career Advice
With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack discusses how pressure builds and what can ease it.
THE LATEST
AbbVie’s blockbuster drug Humira just got another challenger to its share of the market in the United States when its patent expires in 2023.
It was a busy week for clinical trial announcements. Here’s a look.
FUJIFILM Corporation will invest 13 billion yen (about $120 million) to expand the company’s gene therapy business and establish a new Gene Therapy Innovation Center adjacent to its current facility in College Station, Texas and add about 100 jobs.
MD Anderson researchers find abundant cytokine crowds out helper T cells crucial to treatment
In the world of cancer biology, not all biomarkers are created equal. These molecules that alert doctors that an abnormal process may be underway can appear as an array of aberrant proteins, such as hormones, enzymes or signaling molecules, and vary from patient to patient.
ZONTAL will present ZONTAL Space at the Lab of the Future Congress on November 13th-14th, 2019 in Cambridge, UK. ZONTAL Space provides access to the full scope of enterprise data in a single platform and enables fast roll-ins of enterprise scale solutions.
Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, announced it has raised an additional $6.5M in a Series B-3 financing round.
This technology is applicable to both personalized pain treatment and the development of novel pain management therapies, such as non-opioid medications.
MorphoSys AG announced presentation of so far unpublished data on tafasitamab, its proprietary key asset and investigational hemato-oncological drug candidate, at the upcoming 61th American Society of Hematology 2019 Annual Meeting, taking place from December 7-10, 2019 in Orlando, Florida.
Houston, TX Fannin Innovation Studio announces its receipt of a $2,000,000 Phase II Small Business Innovation Research grant from the National Institute of Health Eunice Kennedy Shriver National Institute of Child Health & Human Development for development of its ChorioAnchor device, in partnership with Texas Children’s Hospital, Baylor College of Medicine, and Texas A&M University